""We believe these deals, within two years based on our health improvements, we will be budget neutral,""
""These drugs will not cost us money,""
""The American taxpayers will be getting their money back.""
""This is not about losing weight,""
The Trump administration reached agreements with Novo Nordisk and Eli Lilly to provide blockbuster obesity and Type 2 diabetes medicines to Medicare and Medicaid at negotiated prices. The companies pledged a program price of $245 per month to the programs, with Medicare beneficiary copays set at $50 per month starting in April; state Medicaid programs must opt in separately. Coverage expands to some overweight or obese patients beyond current Type 2 diabetes approvals, subject to BMI and specific comorbidity criteria. Officials expect improved health outcomes and reduced spending on other services to make the deals budget neutral within two years.
Read at www.npr.org
Unable to calculate read time
Collection
[
|
...
]